Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

NCT01850238 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

BIOLOGICAL: AADvac1
OTHER: Placebo

Sponsor

Axon Neuroscience SE